Trials / Sponsors / Myriad Genetic Laboratories, Inc.

Myriad Genetic Laboratories, Inc.

Industry · 16 registered clinical trials.

Status	Trial	Phase	Started
Active Not Recruiting	Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Pr Prostate Cancer	—	2020-04-30
Terminated	EndoPredict® Extended Endocrine Trial (EXET) Primary Invasive Breast Cancer	—	2019-07-02
Completed	A Registry for Hereditary Cancer Risk Assessment and Genetic Testing Prostate Cancer	—	2019-03-06
Completed	Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing Prostate Cancer	—	2018-03-12
Terminated	Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prost Prostate Cancer	—	2017-09-14
Completed	Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes Hereditary Cancer	—	2017-02-13
Withdrawn	Endometriosis Biomarker Discovery Study Chronic Pelvic Pain, Endometriosis	—	2016-09-01
Completed	Bipolar Proteomic Assay Validation Study Major Depressive Disorder, Bipolar I and Bipolar II	—	2016-03-01
Completed	Combined Breast Cancer Risk Study Hereditary Cancer	—	2016-02-06
Terminated	Prospective Prolaris Value and Efficacy Prostate Cancer	—	2015-09-01
Terminated	Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Asse Lung Cancer, NSCLC, NSCLC Adenocarcinoma	—	2015-04-01
Terminated	Registry to Measure the Impact of Adding Genomic Testing Prostate Cancer	—	2014-11-01
Completed	Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prosta Prostate Cancer	—	2014-05-01
Terminated	Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cance Lung Cancer, NSCLC, Lung Adenocarcinoma	—	2014-05-01
Completed	Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients Prostate Cancer	—	2013-04-01
Terminated	Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated Wit Colorectal Cancer, Metastatic	Phase 4	2011-09-01